trial

Study of SPG302 in Adults With Schizophrenia

NCTId NCT06442462
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Active Not Recruiting
Enrollment 32 (estimated)
Sponsored by Spinogenix
Primary completion 2026-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Active Not Recruiting
Enrollment
32 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2024-08-01
Primary completion
2026-03
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
SPG302

Sponsors

SpinogenixLead Sponsor

Investigators

1
David P Walling, PhDPrincipal Investigator

Sites

3 total
Garden Grove, United StatesBox Hill, AustraliaMelbourne, Australia

Linked catalysts

1
Study of SPG302 in Adults With Schizophrenia — primary completion2026-03

Facts & assertions

4 sourced
Enrollment
32
Phase
PHASE2
Primary Completion Date
2026-03
Status
ACTIVE_NOT_RECRUITING
relationships
The graph out of here
drug
SPG302
drug
lead_sponsor
Spinogenix
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
David P Walling, PhD
person